Not FDA-approved1,3Evidence: Animal and lab onlyTissue repair and wound healing

FOXO4-DRI1

Key takeaway

FOXO4-DRI is a lab-designed peptide, made of mirror-image (D) amino acids in reversed sequence, that blocks the FOXO4 protein from holding on to p53 inside ageing, or senescent, cells.1 In a 2017 mouse study it caused senescent cells to die and restored fitness, fur density and kidney function in old and fast-ageing mice; later mouse studies have tested it in other tissues.1,2 No study in people and no FDA approval are reported in the sources reviewed here, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.1,3,5

FOXO4-DRI at a glance

What it isA synthetic D-retro-inverso peptide based on part of the FOXO4 protein, designed to disrupt its interaction with p53, according to the 2017 report that introduced it.1
FDA statusNo FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page does not list it.1,3
Human evidenceNone found: the studies reviewed here used cells and mice.1,2
Evidence strengthAnimal and lab studies only. The cited sources report no completed human study; the research base consists of animal, cell, or other laboratory work. How this label is assigned

What is FOXO4-DRI?

FOXO4-DRI is a synthetic peptide designed by researchers who reported it in 2017. It copies a part of the FOXO4 protein, but uses D-amino acids, the mirror images of natural amino acids, in reversed sequence, a D-retro-inverso design that the authors note can improve a peptide’s potency.1

The 2017 report states that its sequence also carries a cell-entry tag derived from HIV-TAT.1

How is FOXO4-DRI thought to work?

Senescent cells are damaged cells that avoid dying. The 2017 study found that FOXO4 helps keep them alive by holding p53, and that FOXO4-DRI disrupts this hold, pushing p53 out of the nucleus and triggering the cells’ own death program.1

A 2020 study in testosterone-producing Leydig cells found the same effect, describing FOXO4-DRI as a specific FOXO4 blocker.2

What do human studies show?

None of the sources reviewed here describes a study of FOXO4-DRI in people. The 2017 study used human cells in culture and mice.1

In mice, under conditions where it was well tolerated, it neutralized toxicity from the chemotherapy drug doxorubicin and restored fitness, fur density and kidney function in naturally aged and fast-ageing mice.1

In naturally aged mice, it improved the testicular environment and eased an age-related shortfall in testosterone, according to the 2020 study.2

What the evidence base contains

  • Animal or laboratory research A 2017 study in which FOXO4-DRI selectively killed senescent human cells in culture, countered chemotherapy toxicity in mice, and restored fitness, fur density and kidney function in naturally aged and fast-ageing mice.1
  • Animal or laboratory research A 2020 study in which it removed senescent testosterone-producing cells and eased an age-related fall in testosterone in naturally aged mice.2

Evidence-strength label: Animal and lab studies only. How this label is assigned

Is FOXO4-DRI FDA-approved?

None of the sources reviewed here reports an approval of FOXO4-DRI by FDA.1,3

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list FOXO4-DRI.3

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. FOXO4-DRI is not among them.4,5

Timeline

  1. Researchers report FOXO4-DRI as a peptide that clears senescent cells in mice.1
  2. A study reports that FOXO4-DRI eased an age-related fall in testosterone in aged mice.2

What is still unknown?

Whether it has any of these effects in people, and whether it is safe: the studies reviewed here used cells and mice.1,2

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for FOXO4-DRI: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for FOXO4-DRI are a bounded selection, not every registration or paper about FOXO4-DRI. For the years before FOXO4-DRI was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list FOXO4-DRI as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name FOXO4-DRI in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

No FDA approval reported; studied only in cells and animals. Evidence comes from cell and mouse studies. FOXO4-DRI is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of FOXO4-DRI?

No FDA approval reported; studied only in cells and animals. Evidence comes from cell and mouse studies. FOXO4-DRI is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
1
Source years
2
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected clinical trial records, regulatory records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to FOXO4-DRI?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

2Selected dated records
7Connected citations
2Populated source years2022–2025
1/4Record lanes present

Registered human studies

Trial composition

0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.

PubMed bibliography

Publication composition

2 of 2 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 2

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
2

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 2 dated records

Research hub

Explore the FOXO4-DRI evidence record

Open all 2 records →
2Dated records
1Evidence type
2Cited public sources
2Source years

Change ledger

Recently changed for FOXO4-DRI

Open all 2 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes.

PubMed lists PMID 33996787 in Frontiers in bioengineering and biotechnology as Journal Article, with publication-date metadata of 2021-04-29 (day precision). PeptideScanner associated the retained record with the identity slug foxo4-dri. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
February 1, 2022
Evidence lane
Literature metadata
Record added

The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI.

PubMed lists PMID 40593617 in Nature communications as Journal Article, with publication-date metadata of 2025-07-01 (day precision). PeptideScanner associated the retained record with the identity slug foxo4-dri. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
July 4, 2025
Evidence lane
Literature metadata

Official-source collections

Source records for FOXO4-DRI

Open the full research atlas →

Evidence types

Coverage by source year

Selected records span February 1, 2022 to July 4, 2025. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration3
  • U.S. Department of Health and Human Services4
Dated updates connected to this profile · 2

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI.↗

    PubMed lists PMID 40593617 in Nature communications as Journal Article, with publication-date metadata of 2025-07-01 (day precision). PeptideScanner associated the retained record with the identity slug foxo4-dri. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes.↗

    PubMed lists PMID 33996787 in Frontiers in bioengineering and biotechnology as Journal Article, with publication-date metadata of 2021-04-29 (day precision). PeptideScanner associated the retained record with the identity slug foxo4-dri. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging (2017) · PMID 28340339 ↗

    Cell · Official source · Source checked November 16, 2026

  2. 2
    FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice (2020) · PMID 31959736 ↗

    Aging · Official source · Source checked November 16, 2026

  3. 3
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  4. 4
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  5. 5
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026